ZUELLIG PHARMA VIETNAM LTD. (Công Ty TNHH Zuellig Pharma Việt Nam) is one of the most prominent foreign-invested enterprises (FDI) operating in Vietnam’s healthcare and pharmaceutical distribution sector. Founded in March 1999, this wholly owned subsidiary of Zuellig Pharma Pte Ltd. (Singapore) has built a solid presence over more than two decades. Registered under Business ID 0100915699, the company runs a broad operation that includes importing, distributing, marketing, and storing pharmaceutical products across Vietnam.

Headquartered in Hanoi’s Sai Dong B Industrial Park, Zuellig Pharma Vietnam employs over 1,300 staff and maintains major facilities and representative offices in both Hanoi and Ho Chi Minh City. It is led by Mr. Ludovic Pierre Jacques Henri Toulemonde, a French national who currently serves as General Director. The company’s charter capital stands at approximately USD 821,659, with nearly all of it fully paid up.

According to the company’s latest financial data, ZUELLIG PHARMA VIETNAM reported total assets of USD 253.1 million and revenue of USD 376 million in 2023. This marks the third consecutive year of decline in both revenue and asset base. From 2021 to 2023, sales dropped by 36%, while total assets fell nearly 50%. Such downward trends could raise concerns from a risk management perspective, especially in terms of long-term growth strategy and market competitiveness.

However, the company’s profitability tells a more optimistic story. Net profit surged nearly 197% year-on-year in 2023 to reach USD 2.89 million—despite the fall in revenue. This sharp increase suggests that Zuellig has implemented stronger cost controls, more efficient operations, or possibly refined its pricing and supply chain strategy. Owner’s equity has also grown steadily, reaching over USD 50 million in 2023, reinforcing the company’s financial stability and credibility in the market.

From a company credit report and financial risk assessment standpoint, Zuellig Pharma Vietnam reflects the profile of a mature enterprise undergoing a strategic realignment. The drop in revenue raises questions about market share, changing customer dynamics, or regulatory pressures. At the same time, the strengthening of its bottom line signals resilience and effective internal restructuring.

In summary, ZUELLIG PHARMA VIETNAM remains a key player in Vietnam’s pharmaceutical supply chain, with strong backing from its parent group in Singapore. While the company must address its revenue contraction and asset erosion, its improved profitability and solid equity base position it well for continued operations—especially if it sustains a focus on efficiency, compliance, and strategic market positioning. As always, stakeholders are advised to monitor updated financial data and risk metrics to support due diligence and long-term decision-making.